DexCom (DXCM)
Healthcare · Medical - Devices
7 members of Congress have disclosed 18 trades in DexCom (DXCM) since 2020: 8 buys and 10 sales. The most recent was disclosed on May 11, 2026.
- Trades disclosed
- 18
- Members trading
- 7
- Buys / sells
- 8 / 10
- Reported value
- $556K–$1.4M
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at DXCM
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
DXCM: third_quarter 2026 lobbying report
General representation. Legislative and regulatory issues related to policies and payments for continuous glucose monitoring
Public: Oct 20, 2026, 1:07 PM EDTOriginal source ↗DXCM: third_quarter 2026 lobbying report
Issues related to global supply chains Issues related to the Administration's Executive Orders CGM Coverage policy Issues related to sterilization of medical devices Issues related to medical device electronic labeling H.R.1539, Medical Device Electronic Labeling Act Issues related to artificial intelligence and other machine learning advances in healthcare Issues related to advances in diabetes technology Issues related to CY 2026 rulemaking CGM Coverage policies Issues related to breakthrough technology
Public: Oct 20, 2026, 11:00 AM EDTOriginal source ↗DXCM: third_quarter 2026 lobbying report
Issues related to coverage and reimbursement for continuous glucose monitors. Issues related to coverage and reimbursement for continuous glucose monitors.
Public: Oct 20, 2026, 10:03 AM EDTOriginal source ↗DXCM: second_quarter 2026 lobbying report
CGM Coverage policies Issues related to breakthrough technology Issues related to global supply chains Issues related to the Administration's Executive Orders CGM Coverage policy Issues related to sterilization of medical devices Issues related to medical device electronic labeling H.R.1539, Medical Device Electronic Labeling Act Issues related to artificial intelligence and other machine learning advances in healthcare Issues related to advances in diabetes technology Issues related to CY 2026 rulemaking
Public: Jul 20, 2026, 1:21 PM EDTOriginal source ↗DXCM: second_quarter 2026 lobbying report
Issues related to coverage and reimbursement for continuous glucose monitors. Issues related to coverage and reimbursement for continuous glucose monitors.
Public: Jul 20, 2026, 11:46 AM EDTOriginal source ↗
Who traded DXCM
- Rep. Ro Khanna (D-CA-17)4 buys · 1 sale41May 11, 2026
- Sen. Tina Smith (D-MN)0 buys · 3 sales03May 10, 2026
- Rep. Jefferson Shreve (R-IN-6)1 buy · 2 sales12Jun 22, 2025
- Rep. Robert P. Bresnahan, Jr. (R-PA-8)2 buys · 1 sale21Jun 9, 2025
- Rep. Josh Gottheimer (D-NJ-5)0 buys · 2 sales02Oct 15, 2023
- Sen. John Boozman (R-AR)1 buy · 0 sales10Feb 15, 2026
- Rep. Kevin Hern (R-OK-1)0 buys · 1 sale01Jan 15, 2025
All trades
- May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
- May 10, 2026$100K–$250K
Sen. Tina Smith (D-MN)
$100K–$250K · Traded May 7, 2026 · disclosed May 10, 2026 · Spouse
- May 10, 2026$100K–$250K
Sen. Tina Smith (D-MN)
$100K–$250K · Traded Apr 29, 2026 · disclosed May 10, 2026 · Spouse
- Feb 15, 2026$1K–$15K
Sen. John Boozman (R-AR)
$1K–$15K · Traded Jan 26, 2026 · disclosed Feb 15, 2026 · Joint
- Feb 6, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 8, 2025 · disclosed Jun 22, 2025
- Jun 9, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded May 15, 2025 · disclosed Jun 9, 2025
- May 8, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded Apr 7, 2025 · disclosed May 8, 2025
- Apr 28, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded Apr 8, 2025 · disclosed Apr 28, 2025
- Mar 27, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded Feb 25, 2025 · disclosed Mar 27, 2025
- Jan 15, 2025$50K–$100K
Rep. Kevin Hern (R-OK-1)
$50K–$100K · Traded Dec 31, 2024 · disclosed Jan 15, 2025 · Joint
- Nov 8, 2023$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 10, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
- Oct 15, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Sep 12, 2023 · disclosed Oct 15, 2023 · Joint
- Sep 16, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Aug 21, 2023 · disclosed Sep 16, 2023 · Joint
- Apr 16, 2020$250K–$500K
Sen. Tina Smith (D-MN)
$250K–$500K · Traded Mar 17, 2020 · disclosed Apr 16, 2020 · Spouse
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.